Connective Tissue Disorders with MCC DRG Reimbursement Guide

DRG 545 encompasses inpatient hospitalizations for connective tissue disorders with a Major Complication or Comorbidity and represents higher-acuity, higher-cost cases. This category matters for inpatient reimbursement because the presence of a Major Complication or Comorbidity increases the Diagnosis-Related Group weight and therefore the Medicare payment for the episode of care.

DRG 545 Overview

DRG 545 covers inpatient stays for connective tissue disorders when a Major Complication or Comorbidity is present, typically including severe systemic inflammatory conditions, severe autoimmune manifestations, and complications such as sepsis or organ dysfunction related to the underlying disease. This Diagnosis-Related Group groups cases with higher resource use and clinical complexity, which affects Medicare payment through higher relative weights and reimbursement levels compared with cases without a Major Complication or Comorbidity. Accurate reporting of principal diagnosis, secondary diagnoses, and procedures drives correct assignment to this Diagnosis-Related Group and corresponding payment. Coding specificity for severity and documented complications is central to classifying these hospitalizations.

DRG 545 Overview

Acute immunomodulatory intervention trials: Studies testing short-term inpatient interventions (for example, high-dose corticosteroid protocols, plasma exchange, or IV immunoglobulin regimens) for patients admitted with severe, life-threatening flares or complications of connective tissue disorders and a major complication or comorbidity (MCC) such as organ failure, diffuse alveolar hemorrhage, or severe infection. These trials enroll hospitalized adults with acute presentations that require immediate escalation of care; they measure time to stabilization, duration of intensive care, and in-hospital morbidity and mortality. Results inform hospital clinical pathways and resource allocation decisions for high-cost, high-acuity admissions under this DRG.
Comparative effectiveness studies of inpatient management strategies: Head-to-head evaluations compare different inpatient care approaches (for example, early aggressive immunosuppression versus stepwise escalation, multidisciplinary team models versus standard care, or different venous thromboembolism prophylaxis strategies) in patients with connective tissue diseases complicated by serious comorbid conditions like sepsis, renal failure, or thrombotic events. These studies typically include heterogeneous hospitalized populations stratified by severity and comorbidity burden and assess outcomes such as length of stay, complication rates, readmission risk, and short-term functional status. Findings are directly relevant to providers and payers because they can identify care patterns that reduce complications and costs while maintaining quality for complex DRG 545 admissions.
Post-discharge outcomes and transitional care trials: Research focused on interventions initiated during the hospital stay to improve post-discharge outcomes—such as structured discharge planning, early outpatient specialty follow-up, home-based monitoring, or medication reconciliation programs—for patients hospitalized with connective tissue disorders and MCCs. These studies enroll patients at discharge or shortly after and measure 30- to 90-day readmissions, emergency visits, medication adherence, and disease-specific relapse rates. Demonstrating reduced readmissions and better outpatient disease control is important to payers and health systems aiming to manage total episode costs and improve long-term outcomes for this high-risk DRG population.

Acute immunomodulatory intervention trials: Studies testing short-term inpatient interventions (for example, high-dose corticosteroid protocols, plasma exchange, or IV immunoglobulin regimens) for patients admitted with severe, life-threatening flares or complications of connective tissue disorders and a major complication or comorbidity (MCC) such as organ failure, diffuse alveolar hemorrhage, or severe infection. These trials enroll hospitalized adults with acute presentations that require immediate escalation of care; they measure time to stabilization, duration of intensive care, and in-hospital morbidity and mortality. Results inform hospital clinical pathways and resource allocation decisions for high-cost, high-acuity admissions under this DRG.
Comparative effectiveness studies of inpatient management strategies: Head-to-head evaluations compare different inpatient care approaches (for example, early aggressive immunosuppression versus stepwise escalation, multidisciplinary team models versus standard care, or different venous thromboembolism prophylaxis strategies) in patients with connective tissue diseases complicated by serious comorbid conditions like sepsis, renal failure, or thrombotic events. These studies typically include heterogeneous hospitalized populations stratified by severity and comorbidity burden and assess outcomes such as length of stay, complication rates, readmission risk, and short-term functional status. Findings are directly relevant to providers and payers because they can identify care patterns that reduce complications and costs while maintaining quality for complex DRG 545 admissions.
Post-discharge outcomes and transitional care trials: Research focused on interventions initiated during the hospital stay to improve post-discharge outcomes—such as structured discharge planning, early outpatient specialty follow-up, home-based monitoring, or medication reconciliation programs—for patients hospitalized with connective tissue disorders and MCCs. These studies enroll patients at discharge or shortly after and measure 30- to 90-day readmissions, emergency visits, medication adherence, and disease-specific relapse rates. Demonstrating reduced readmissions and better outpatient disease control is important to payers and health systems aiming to manage total episode costs and improve long-term outcomes for this high-risk DRG population.

OpenPayer

Connective Tissue Disorders with MCC: Inpatient Reimbursement Overview

Sign up for drg 545 policy alerts

DRG 545 Overview

OpenPayer

Connective Tissue Disorders with MCC: Inpatient Reimbursement Overview

Sign up for drg 545 policy alerts

DRG 545 Overview

Clinical Trials

Related Codes

References

Clinical Trials

Related Codes

References